Ishrak: Medtronic has eyes on overseas acquisitions
Medtronic ($MDT) is eyeing overseas acquisitions and has roughly $2 billion a year to spend, said Omar Ishrak at the J.P. Morgan Healthcare Conference in San Francisco, Bloomberg notes. However, "[w]e need to have a far more disciplined approach to acquisitions," said Ishrak. "That may be tough, but we'll have to find a way to do it. It's going to be a big hurdle to get any form of dilution from us." News
More stories about Medtronic
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: